Inherited Genetic Mutations and Polymorphisms in Malignant Mesothelioma: A Comprehensive Review

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Jun 21

PMID 32560575

Citations 23

Authors

Vasiliki Panou

Oluf Dimitri Roe

Affiliations

Soon will be listed here.

Abstract

Malignant mesothelioma (MM) is mainly caused by air-born asbestos but genetic susceptibility is also suspected to be a risk factor. Recent studies suggest an increasing number of candidate genes that may predispose to MM besides the well-characterized BRCA1-associated protein-1 gene. The aim of this review is to summarize the most important studies on germline mutations for MM. A total of 860 publications were retrieved from Scopus, PubMed and Web of Science, of which 81 met the inclusion criteria and were consider for this review. More than 50% of the genes that are reported to predispose to MM are involved in DNA repair mechanisms, and the majority of them have a role in the homologous recombination pathway. Genetic alterations in tumor suppressor genes involved in chromatin, transcription and hypoxia regulation have also been described. Furthermore, we identified several single nucleotide polymorphisms (SNPs) that may promote MM tumorigenesis as a result of an asbestos-gene interaction, including SNPs in DNA repair, carcinogen detoxification and other genes previously associated with other malignancies. The identification of inherited mutations for MM and an understanding of the underlying pathways may allow early detection and prevention of malignancies in high-risk individuals and pave the way for targeted therapies.

Citing Articles

Bayesian analysis of the rate of spontaneous malignant mesothelioma among BAP1 mutant mice in the absence of asbestos exposure.

Nielsen D, Hsu M, Zapata 3rd M, Ciavarra G, van Zyl L Sci Rep. 2025; 15(1):169.

PMID: 39747518 PMC: 11697272. DOI: 10.1038/s41598-024-84069-w.

The role of pathologists in the diagnosis of occupational lung diseases: an expert opinion of the European Society of Pathology Pulmonary Pathology Working Group.

Calabrese F, Montero-Fernandez M, Kern I, Pezzuto F, Lunardi F, Hofman P Virchows Arch. 2024; 485(2):173-195.

PMID: 39030439 PMC: 11329671. DOI: 10.1007/s00428-024-03845-1.

Germline variants predispose to mesothelioma by impairing DNA repair and calcium signaling.

Novelli F, Yoshikawa Y, Vitto V, Modesti L, Minaai M, Pastorino S Proc Natl Acad Sci U S A. 2024; 121(29):e2405231121.

PMID: 38990952 PMC: 11260134. DOI: 10.1073/pnas.2405231121.

Asbestos ban policies and mesothelioma mortality in Greece.

Gogou E, Hatzoglou C, Siachpazidou D, Zarogiannis S, Gourgoulianis K BMC Public Health. 2024; 24(1):1177.

PMID: 38671450 PMC: 11055379. DOI: 10.1186/s12889-024-18030-x.

POLD1 Is Required for Cell Cycle Progression by Overcoming DNA Damage in Malignant Pleural Mesothelioma.

Shimizu D, Ishibashi M, Yamada T, Toda Y, Hosogi S, Ashihara E Cancer Genomics Proteomics. 2024; 21(2):158-165.

PMID: 38423601 PMC: 10905272. DOI: 10.21873/cgp.20437.

References

Birch J, Alston R, McNally R, Evans D, Kelsey A, Harris M . Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene. 2001; 20(34):4621-8. DOI: 10.1038/sj.onc.1204621. View

Hung R, Brennan P, Canzian F, Szeszenia-Dabrowska N, Zaridze D, Lissowska J . Large-scale investigation of base excision repair genetic polymorphisms and lung cancer risk in a multicenter study. J Natl Cancer Inst. 2005; 97(8):567-76. DOI: 10.1093/jnci/dji101. View

Sneddon S, Leon J, Dick I, Cadby G, Olsen N, Brims F . Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma. Gene. 2015; 563(1):103-5. DOI: 10.1016/j.gene.2015.03.031. View

Ambrosone C, Sweeney C, Coles B, Thompson P, McClure G, Korourian S . Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res. 2001; 61(19):7130-5. View

Pilarski R, Cebulla C, Massengill J, Rai K, Rich T, Strong L . Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases. Genes Chromosomes Cancer. 2013; 53(2):177-82. PMC: 4041196. DOI: 10.1002/gcc.22129. View

Cui M, You L, Ren X, Zhao W, Liao Q, Zhao Y . Long non-coding RNA PVT1 and cancer. Biochem Biophys Res Commun. 2016; 471(1):10-4. DOI: 10.1016/j.bbrc.2015.12.101. View

Roe O, Stella G . Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic. Eur Respir Rev. 2015; 24(135):115-31. PMC: 9487774. DOI: 10.1183/09059180.00007014. View

Maxwell P, Wiesener M, Chang G, Clifford S, Vaux E, Cockman M . The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399(6733):271-5. DOI: 10.1038/20459. View

Nakas A, Waller D . Predictors of long-term survival following radical surgery for malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2014; 46(3):380-5. DOI: 10.1093/ejcts/ezt664. View

10.

Hirvonen A, Pelin K, Tammilehto L, Karjalainen A, Mattson K, Linnainmaa K . Inherited GSTM1 and NAT2 defects as concurrent risk modifiers in asbestos-related human malignant mesothelioma. Cancer Res. 1995; 55(14):2981-3. View

11.

Nishikawa H, Wu W, Koike A, Kojima R, Gomi H, Fukuda M . BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity. Cancer Res. 2009; 69(1):111-9. DOI: 10.1158/0008-5472.CAN-08-3355. View

12.

Ohar J, Cheung M, Talarchek J, Howard S, Howard T, Hesdorffer M . Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer. Cancer Res. 2016; 76(2):206-15. PMC: 4715907. DOI: 10.1158/0008-5472.CAN-15-0295. View

13.

Catic A, Suh C, Hill C, Daheron L, Henkel T, Orford K . Genome-wide map of nuclear protein degradation shows NCoR1 turnover as a key to mitochondrial gene regulation. Cell. 2013; 155(6):1380-95. PMC: 4068507. DOI: 10.1016/j.cell.2013.11.016. View

14.

Husain A, Colby T, Ordonez N, Allen T, Attanoos R, Beasley M . Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2017; 142(1):89-108. DOI: 10.5858/arpa.2017-0124-RA. View

15.

Karamurzin Y, Zeng Z, Stadler Z, Zhang L, Ouansafi I, Al-Ahmadie H . Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature. Hum Pathol. 2012; 43(10):1677-87. DOI: 10.1016/j.humpath.2011.12.012. View

16.

Hakimi A, Ostrovnaya I, Reva B, Schultz N, Chen Y, Gonen M . Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res. 2013; 19(12):3259-67. PMC: 3708609. DOI: 10.1158/1078-0432.CCR-12-3886. View

17.

Toumpanakis D, Theocharis S . DNA repair systems in malignant mesothelioma. Cancer Lett. 2011; 312(2):143-9. DOI: 10.1016/j.canlet.2011.08.021. View

18.

Yoon S, Woo S, Kang J, Kim K, Shin H, Gwak H . NF-κB and STAT3 cooperatively induce IL6 in starved cancer cells. Oncogene. 2011; 31(29):3467-81. DOI: 10.1038/onc.2011.517. View

19.

de Gooijer C, Borm F, Scherpereel A, Baas P . Immunotherapy in Malignant Pleural Mesothelioma. Front Oncol. 2020; 10:187. PMC: 7047444. DOI: 10.3389/fonc.2020.00187. View

20.

Pastorino S, Yoshikawa Y, Pass H, Emi M, Nasu M, Pagano I . A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations. J Clin Oncol. 2018; :JCO2018790352. PMC: 7162737. DOI: 10.1200/JCO.2018.79.0352. View